News and Events
.png)
More News
-
Independent Chair appointed to lead QEII Health and Biomedical Precinct 12 December 2025 Western Australia’s Health and Biomedical Precinct at Queen Elizabeth II Medical Centre (QEII) today reached a significant milestone with the appointment of Ms Paula Rogers as the inaugural Independent Chair of the Precinct Leadership Group (PLG). Supported by a $1.9 million investment from the WA Government, the PLG is tasked with guiding the development of the Precinct’s long-term vision and governance structure. The aim is for the Precinct to become an independently governed, self-sustaining entity by 2027, enhancing collaboration between universities, health service providers, and industry. The QEII Precinct is set to become one of the largest health and biomedical hubs in the southern hemisphere, driving improvements in research translation and innovation across WA. Ms Rogers brings extensive experience in stakeholder engagement and strategic leadership, having previousl... -
Spotlight on RHD 2025 Information Session: Recording and slides now available 10 December 2025 The Office of Medical Research and Innovation (OMRI) recently hosted a virtual information session for the inaugural Future Health Research and Innovation (FHRI) Fund Spotlight Program, focusing on Rheumatic Heart Disease (RHD). The session, led by Stacey Waters, provided an overview of the Spotlight Program’s objectives, application process, and the unique opportunity it presents for Western Australia’s health and medical research sector. Attendees learned about the two-stage funding model—offering up to $25 million over five years—and the program’s emphasis on sector-wide collaboration, community engagement, and translational impact. Key highlights included: The Spotlight Program is the flagship initiative of the FHRI Fund Strategy 2025–30, designed to address a major WA health challenge each year. The 2025–26 theme is RHD, a preventa... -
WA’s innovation start-ups take off with WAVCI support 10 December 2025 Western Australia’s innovation ecosystem is gaining strength through the Western Australian Venture Capital Initiative (WAVCI), which has delivered strong results in its first year. The initiative is designed to expand the pool of venture capital available in WA and accelerate the growth of high-potential businesses across the State’s priority sectors. This funding will help founders access critical early-stage capital, enabling growth, commercialisation, and job creation. Seven venture capital funds have been appointed under the program: Artesian, Brandon Capital Partners and Health Translation Group will focus on health and medical opportunities, while Melt Ventures, Skalata Ventures, Purpose Ventures and FundWA will focus on other priority sectors for WA. All participating funds are establishing or expanding a WA presence, bringing new expertise, networks, and investment o... -
Nominate to become a FHRI Fund Advisory Council Member 05 December 2025 In accordance with theWestern Australian (WA) Future Health Research and Innovation (FHRI) Fund Act 2012 (the Act),the Minister for Medical Research invites expressions of interest (EOIs) from suitably qualified, WA based people, to fill the following two FHRI Fund Advisory Council Member vacancies: a member with experience dealing with issues related to the health of Aboriginal people living in WA a member with expertise in health and medical research in WA The Advisory Council plays a pivotal role advising the WA government on the strategic direction and funding allocations that drive health and medical research and innovation in WA. Established under Section 4G of the Act, the Advisory Council leads strategy and priority development for the FHRI Fund and provides expert recommendations and assurance to ensure transparent and strategically aligned investment in health and med... -
WA opens world-leading RNA facility to accelerate cancer research 03 December 2025 On 3 December 2025, Western Australia marked a major milestone in medical innovation with the official opening of the RNA Innovation Foundry (RIF) at The University of Western Australia (UWA). The new facility is set to fast-track the development of personalised RNA-based cancer treatments, positioning WA as a national leader in RNA research and precision medicine. The RIF is Australia’s first centre dedicated exclusively to applying RNA technology to oncology, designed to manufacture high-quality mRNA and expedite breakthroughs for aggressive and treatment-resistant cancers. Researchers, clinicians, and patient advocates will collaborate to design, produce, and test pilot RNA products, aiming to improve outcomes for a wide range of cancers. The Foundry was developed in partnership with the Australian Centre for RNA Therapeutics in Cancer (ACRTC) at UWA and is supported by a $6.8...
Last Updated:
22/05/2025